The estimated Net Worth of Yasir B. Al Wakeel is at least $786 mil dollars as of 6 July 2023. Dr Wakeel owns over 9,617 units of Kronos Bio stock worth over $332,223 and over the last 9 years he sold KRON stock worth over $32,535. In addition, he makes $421,257 as CFO & Head of Corp. Devel. at Kronos Bio.
Dr has made over 4 trades of the Kronos Bio stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 9,617 units of KRON stock worth $16,830 on 6 July 2023.
The largest trade he's ever made was exercising 17,241 units of Kronos Bio stock on 17 July 2018 worth over $99,998. On average, Dr trades about 2,420 units every 107 days since 2015. As of 6 July 2023 he still owns at least 346,102 units of Kronos Bio stock.
You can see the complete history of Dr Wakeel stock trades at the bottom of the page.
Dr. Yasir B. Al-Wakeel BCh, BM, MA is the CFO & Head of Corp. Devel. at Kronos Bio.
As the CFO & Head of Corp. Devel. of Kronos Bio, the total compensation of Dr MA at Kronos Bio is $421,257. There are 2 executives at Kronos Bio getting paid more, with Jorge F. DiMartino M.D., Ph.D. having the highest compensation of $765,105.
Dr MA is 39, he's been the CFO & Head of Corp. Devel. of Kronos Bio since . There are 9 older and 1 younger executives at Kronos Bio. The oldest executive at Kronos Bio, Inc. is Dr. Norbert W. Bischofberger Ph.D., 65, who is the Pres, CEO & Director.
Yasir's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger y Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio executives and other stock owners filed with the SEC include: